Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Leath CA 3rd, Cella D, Sun Z, Patel S, Tang Z, Ratajczak CK, Aghajanian C, Bookman MA. Coleman RL, et al. Among authors: leath ca 3rd. Eur J Cancer. 2025 Jun 17;225:115587. doi: 10.1016/j.ejca.2025.115587. Online ahead of print. Eur J Cancer. 2025. PMID: 40561681
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Thaker PH, Richardson DL, Hagemann AR, Holloway RW, Reed M, Bergman MK, Pothuri B, DePasquale S, Scalici JM, Bregar AJ, Darus CJ, Finkelstein K, Leath CA 3rd, Bell M, Warshal DP, Agajanian R, Indermaur MD, Mendivil AA, Provencher DM, Wei LJ, Borys N, Musso L, Lindborg SR, Faller DV, Anwer K, Bradley WH. Thaker PH, et al. Among authors: leath ca 3rd. Gynecol Oncol. 2025 Jun;197:182-191. doi: 10.1016/j.ygyno.2025.04.578. Epub 2025 Jun 3. Gynecol Oncol. 2025. PMID: 40461366 Free article. Clinical Trial.
Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
Castellano T, ElHabr AK, Washington C, Ting J, Zhang YJ, Musa F, Berksoy E, Moore K, Randall L, Chhatwal J, Ayer T, Leath CA 3rd. Castellano T, et al. Among authors: leath ca 3rd. PLoS One. 2025 May 20;20(5):e0324971. doi: 10.1371/journal.pone.0324971. eCollection 2025. PLoS One. 2025. PMID: 40392784 Free PMC article.
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy.
Tarney CM, Tian C, Randall LM, Hussain SA, Javadian P, Cronin SP, Drayer S, Chan JK, Kapp DS, Hamilton CA, Leath CA 3rd, Benbrook DM, Washington CR, Moore KN, Bateman NW, Conrads TP, Phippen NT, Maxwell GL, Darcy KM. Tarney CM, et al. Among authors: leath ca 3rd. JAMA Netw Open. 2025 May 1;8(5):e2510717. doi: 10.1001/jamanetworkopen.2025.10717. JAMA Netw Open. 2025. PMID: 40372751 Free PMC article.
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F. Van Gorp T, et al. Among authors: leath ca 3rd. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. Lancet Oncol. 2025. PMID: 40179908 Clinical Trial.
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Leath CA 3rd, Deng W, Mell LK, Richardson DL, Walker JL, Holman LL, Lea JS, Amarnath SR, Santos-Reyes LJ, Arend RC, Mayadev J, Jegadeesh N, DiSilvestro P, Chon HS, Ghamande SA, Gao L, Albuquerque K, Chino JP, Donnelly E, Feddock JM, Lowenstein J, Quick AM, Kunos CM, MacKay H, Aghajanian C, Monk BJ. Leath CA 3rd, et al. Gynecol Oncol. 2025 Apr;195:122-133. doi: 10.1016/j.ygyno.2025.03.007. Epub 2025 Mar 17. Gynecol Oncol. 2025. PMID: 40101606 Clinical Trial.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: leath ca 3rd. Nat Med. 2025 May;31(5):1539-1546. doi: 10.1038/s41591-025-03566-1. Epub 2025 Mar 5. Nat Med. 2025. PMID: 40044930 Clinical Trial.
147 results